531
Views
39
CrossRef citations to date
0
Altmetric
Original Articles

A review of the current situation of aflatoxin M1 in cow’s milk in Serbia: risk assessment and regulatory aspects

, , , , , & show all
Pages 1617-1631 | Received 27 Mar 2017, Accepted 07 Jul 2017, Published online: 17 Aug 2017
 

ABSTRACT

The aim of this systematic review is to provide information regarding the incidence and levels of aflatoxin M1 (AFM1) in raw and heat processed cow’s milk in Serbia during 2015–16 and to compare these with collected data on the occurrence of AFM1 in raw milk and dairy products during the last decade in our region. Estimation of dietary exposure (EDI) and hazard index (HI) calculations for different age groups of the population were also carried out, based on the AFM1 content of milk samples and on available food consumption data in Serbia. AFM1 was detected in 69.9% (984/1408) of raw milk samples in 2015 versus 84.9% (3094/3646) in 2016, while in heat-processed milk, AFM1 was detected in 77.8% (364/468) in 2015 versus 98.5% (753/765) in 2016. On the basis of the obtained results, 450 (9%) of raw and 14 (1.1%) of heat-processed milk samples were contaminated with AFM1 levels above the maximum permitted level in Serbia (0.25 μg kg−1). However, a large percentage of raw and heat processed milk in Serbia (30.1% and 17.3%, respectively) was contaminated with AFM1 levels above the maximum permitted level regulated in the European Union (0.05 μg kg−1). Therefore, in order to protect consumer health, it is extremely important to further control the level of aflatoxins in milk, and this should be considered as a high priority for risk management actions.

Disclosure statement

No potential conflict of interest was reported by the authors.​​​

Additional information

Funding

This study was supported by the projects no. TR 31008, funded by the Ministry of Education, Science and Technological Development of the Republic of Serbia. Part of this research was dedicated to COST action TD 1404 - Network for Evaluation of One Health (NEOH), supported by COST (European Cooperation in Science and Technology).​​​

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.